GlassScriptPhysician profile
Megan S Wheelden
NPI 1245677301
$4,424.02
in general payments reported to CMS, 2019-2025
11 companies · $3,791 in 2025
The $3,791 reported for 2025 was more than what 78% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $435 · 2021: $199 · 2025: $3,791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $1,838 · Travel and Lodging: $1,494 · Food and Beverage: $459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $1,837.50 |
| Travel and Lodging | $1,494.42 |
| Food and Beverage | $458.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $3,651.18 | 2025 | Cabometyx |
| Caris Mpi, INC. | $139.34 | 2025 | Mi Cancer Seek |
| Janssen Biotech, INC. | $123.29 | 2021 | |
| Genzyme Corporation | $113.92 | 2019 | |
| Foundation Medicine, INC. | $97.69 | 2019 | |
| Seagen INC. | $75.99 | 2019 | |
| Jazz Pharmaceuticals INC. | $75.67 | 2019 | |
| Myovant Sciences INC. | $75.60 | 2021 | |
| Celgene Corporation | $71.34 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Wheelden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.